The research, published Thursday in JAMA Ophthalmology, found that after one year, more than twice as many people on GLP-1 drugs developed neovascular age-related macular degeneration compared to similar people who were not taking the drugs
doi: 10.1158/1541-7786.MCR-16-0158 196 YangZSuWWeiXQuSZhaoDZhouJet al
If approved, it will be the first GLP-1 to treat MASH, and an FDA decision is anticipated by the third quarter of 2025
Administration Schedule: Frequency: Daily injections Timing: Administered in the morning or post-workout to maximize absorption and effectiveness
The brand's own FAQ states that "certain medications, specific formulations, or fulfillment options may vary" by state due to pharmacy licensing, a point covered in more detail in the pharmacy section below
Version history isnt available either, which could be a valuable addition for users who frequently revise or collaborate on evolving ideas